Multiple endocrine neoplasia syndromes associated with mutation of p27

Journal of Endocrinological Investigation

Volumn 36, Issue 9, 2013, Pages 781-787

  Lee, M ^a   Pellegata, N S ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cdkn1b; MEN4; MENX; Multiple endocrine neoplasias; p27

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P27;

DNA POLYMORPHISM; ENDOCRINE DISEASE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GERM LINE; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PROTEIN FUNCTION; SHORT SURVEY; SOMATIC MUTATION;

ADENOMA; ADULT; ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GERM-LINE MUTATION; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION, MISSENSE; PARATHYROID NEOPLASMS; PITUITARY NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS;

EID: 84891703709     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/9021     Document Type: Short Survey

References (43)

1. Lakhani VT, You YN, Wells SA. The multiple endocrine neoplasia syndromes. Annu Rev Med 2007, 58: 253-65.
2. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86: 5658-71.
3. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005, 5: 367-75.
4. Koch CA. Molecular pathogenesis of MEN2-associated tumors. Fam Cancer 2005, 4: 3-7.
5. Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis 2006, 1: 45.
6. Lips CJ, Dreijerink KM, Hoppener JW. Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation. Clinics (Sao Paulo) 2012, 67 (Suppl 1): 49-56.
7. Toledo SP, dos Santos MA, Toledo Rde A, Lourenco DM Jr. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics (Sao Paulo) 2006, 61: 59-70.
8. Ozawa A, Agarwal SK, Mateo CM, et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab 2007, 92: 1948-51.
9. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006, 103: 15558-63.
10. Fritz A, Walch A, Piotrowska K, et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 2002, 62: 3048-51.
11. Molatore S, Kiermaier E, Jung CB, et al. Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol Cancer 2010, 9: 116.
12. Wlodarska I, Marynen P, La Starza R, Mecucci C, Van den Berghe H. The ETV6, CDKN1B and D12S178 loci are involved in a segment commonly deleted in various 12p aberration in different hematological malignancies. Cytogenet Cell Genet 1996, 72: 229-35.
13. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9: 1149-63.
14. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997, 11: 1464-78.
15. Dijkers PF, Medema RH, Pals C, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 2000, 20: 9138-48.
16. Servant MJ, Coulombe P, Turgeon B, Meloche S. Differential regulation of p27(Kip1) expression by mitogenic and hypertrophic factors: Involvement of transcriptional and posttranscriptional mechanisms. J Cell Biol 2000, 148: 543-56.
17. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997, 272: 7093-8.
18. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269: 682-5.
19. Kamura T, Hara T, Matsumoto M, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 2004, 6: 1229-35.
20. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999, 1: 193-9.
21. Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002, 277: 14355-8.
22. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008, 8: 253-67.
23. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997, 3: 231-4.
24. Hershko D, Bornstein G, Ben-Izhak O, et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001, 91: 1745-51.
25. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000, 183: 10-7.
26. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002, 8: 1145-52.
27. Besson A, Hwang HC, Cicero S, et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007, 21: 1731-46.
28. Chang BL, Zheng SL, Isaacs SD, et al. A polymorphism in the CD-KN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 2004, 64: 1997-9.
29. Figueiredo JC, Knight JA, Cho S, et al.Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. BMC Cancer 2007, 7: 99-106.
30. Li G, Sturgis EM, Wang LE, et al. Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clinical Cancer Research 2004, 10: 3996-4002.
31. Wei F, Xu J, Tang L, et al. p27(Kip1) V109G polymorphism and cancer risk: a systematic review and meta-analysis. Cancer Biother Radiopharm 2012, 27: 665-71.
32. Landa I, Montero-Conde C, Malanga D, et al. Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. Endocr Relat Cancer 2010, 17: 317-28.
33. Morosetti R, Kawamata N, Gombart AF, et al. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995, 86: 1924-30.
34. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP. p27/Kip1 mutation found in breast cancer. Cancer Res 1996, 56: 2400-4.
35. Pappa V, Papageorgiou S, Papageorgiou E, et al. A novel p27 gene mutation in a case of unclassified myeloproliferative disorder. Leuk Res 2005, 29: 229-31.
36. Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A. Somatic mutation and germline sequence abnormalities in CD-KN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab 2011, 96: E701-6.
37. Occhi G, Regazzo D, Trivellin G, et al. A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes MEN4 Phenotype. PLOS Genetics 2013, 9: e1003350.
38. Malanga D, De Gisi S, Riccardi M, et al. Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur J Endocrinol 2012, 166: 551-60.
39. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin EndocrinolMetab 2009, 94: 1826-34.
40. Georgitsi M, Raitila A, Karhu A, et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007, 92: 3321-5.
41. Belar O, De La Hoz C, Perez-Nanclares G, et al. Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin Endocrinol (Oxf) 2012, 76: 719-24.
42. Molatore S, Marinoni I, Lee M, et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat 2010, 31: E1825-35.
43. Tichomirowa MA, Lee M, Barlier A, et al. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr Relat Cancer 2012, 19: 233-41.